Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Complement Ther Med. 2020 Jan;48:102283. doi: 10.1016/j.ctim.2019.102283. Epub 2019 Dec 17.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Curcumin is the anti-inflammatory, antioxidant, anti-diabetic and also anti-hyperlipidemia agent and uses as herbal medicine for treating liver diseases.
The present systematic review and meta-analysis was conducted to investigate the effects of curcumin supplementation on metabolic markers and anthropometric parameters in patients with (NAFLD).
PubMed, Embase, Scopus, Web of Science and Cochrane Library were systematically searched to identify relevant randomized controlled trials (RCTs) investigating the effects of curcumin supplementation on the arms of this study in patients with NAFLD up to September 2019. Mean difference (MD) was pooled using a random effects model. Potential publication bias was assessed using Egger's weighted regression tests.
After excluding irrelevant records, 9 RCTs included in this meta-analysis. Pooled results of included studies indicated a significant reduction in alanine transaminase (ALT), aspartate transaminase (AST), serum total cholesterol (TC), low density lipoprotein (LDL), fasting blood sugar (FBS), HOMA-IR, serum insulin and waist circumference (WC), but not in serum triglyceride (TG), high density lipoprotein (HDL), HbA1c, body weight and body mass index (BMI) following curcumin supplementation. Additionally, age- and baseline TC-based subgroup analysis indicated a significant reduction in TG and also duration- and dosage-based showed a significant change in BMI.
The current study revealed that curcumin supplementation has favorable effect on metabolic markers and anthropometric parameters in patients with NAFLD.
非酒精性脂肪性肝病（NAFLD）是世界上最常见的肝脏疾病。姜黄素是一种具有抗炎、抗氧化、抗糖尿病和抗高血脂作用的草药，可用于治疗肝脏疾病。
本系统评价和荟萃分析旨在研究姜黄素补充剂对（NAFLD）患者代谢标志物和人体测量参数的影响。
系统检索 PubMed、Embase、Scopus、Web of Science 和 Cochrane Library，以确定截至 2019 年 9 月，关于姜黄素补充剂对 NAFLD 患者干预措施的影响的相关随机对照试验（RCT）。使用随机效应模型汇总均数差（MD）。使用 Egger 加权回归检验评估潜在的发表偏倚。
排除不相关的记录后，共有 9 项 RCT 纳入本荟萃分析。纳入研究的汇总结果表明，姜黄素补充剂可显著降低丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、血清总胆固醇（TC）、低密度脂蛋白（LDL）、空腹血糖（FBS）、HOMA-IR、血清胰岛素和腰围（WC），但对血清甘油三酯（TG）、高密度脂蛋白（HDL）、糖化血红蛋白（HbA1c）、体重和体重指数（BMI）无影响。此外，年龄和基线 TC 亚组分析表明 TG 显著降低，而基于疗程和剂量的亚组分析表明 BMI 显著变化。
本研究表明，姜黄素补充剂对 NAFLD 患者的代谢标志物和人体测量参数有良好的影响。
